STAT+: GLP-1 drugs are almost single-handedly forcing employers to reconsider workers’ health care

Another hospital system sues CVS Health, how Medicaid cuts will change everything, and more from Health Care Inc. Adobe Bob covers the money in health care, focusing on health insurance and hospitals. His stories delve into Medicare Advantage, opaque prescription drug benefits, and how much executives actually make. He is also the author of the Health Care Inc. newsletter. You can reach Bob on Signal at bobjherman.09. This is the online version of STAT’s weekly email newsletter Health Care Inc. Sign up here. If you’re not doing anything tomorrow at 2 p.m. ET, come watch a webinar about how federal health agencies are stonewalling the press. I’ll be on the panel with Sheryl Gay Stolberg of the New York Times, Robert King of Politico, Caitlin Vogus of the Freedom of the Press Foundation, and Joyce Frieden of MedPage Today. RSVP here, and as always, hurl your feedback at me: [email protected]. Are GLP-1s breaking employers? GLP-1 drugs are almost single-handedly forcing employers to reconsider how they pay for their workers’ care. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe Business of Health Care Reporter Bob covers the money in health care, focusing on health insurance and hospitals. His stories delve into Medicare Advantage, opaque prescription drug benefits, and how much executives actually make. He is also the author of the Health Care Inc. newsletter. You can reach Bob on Signal at bobjherman.09.